靶向小分子创新药物  

Innovative Medicines of Targeting Small Molecules

作　　者：唐军[1] 傅大煦[1] 

机构地区：[1]上海新药研究开发中心,上海201203

出　　处：《现代生物医学进展》2010年第20期3997-4000,3972,共5页Progress in Modern Biomedicine

基　　金：上海市"科技创新行动计划"重点项目("上海十二五科技发展规划战略研究"软课题)(10692105100)

摘　　要：寻找药物新靶点是全球创新药物研究激烈竞争的焦点。"组学"、生物信息学、系统生物学、药物筛选现代检测技术等新理论、新技术的发展使新的筛选模型和评价技术不断取得突破。靶向抗肿瘤药物的开发是靶向小分子创新药物的重点任务,多靶点的抗肿瘤药物开发及新靶点的发现是抗肿瘤药物研发的新趋势。The discovery of new targets is the focus of competition in global new drugs research and development. The sustained breakthrough in screening assays and valuation technology is based on updated theories and technologies of genomics, proteomics, bioin- formatics, system biology, modern detection technology etc. The key task of R＆D in targeted small molecular drugs is anti-cancer targeted drugs. The trend of R＆D in anti-cancer drugs is design of multi-targets drug and discovery of new targets.

关 键 词：新靶标 药物评价 筛选模型 靶向抗肿瘤药物 泛素-蛋白酶体通路(UPS) 极光激酶 RAS蛋白 

分 类 号：R155.5[医药卫生—营养与食品卫生学] R378[医药卫生—公共卫生与预防医学]